We studied the effect of the following factors on the absorbed dose by tumor and OARs: the competition between labeled and unlabeled ligands in binding to the binding sites, multi-bolus injection instead of a single bolus injection, and the strength of ligand-albumin affinity. The gene discussed is ALB; the disease is neoplasm.